TOPLINE:
Patients who received zuranolone 50 mg/d demonstrated significantly greater improvement in depressive symptoms than those who received placebo, with a rapid onset of effect.METHODOLOGY:
The US Food and Drug Administration has accepted filing of a new drug application for zuranolone, a neuroactive steroid that targets g-aminobutyric acid type A receptors (GABA A R), for the treatment of major depressive disorder (MDD) and postpartum depression.
Patients who received zuranolone 50 mg/d demonstrated significantly greater improvement in depressive symptoms than those who received placebo, with a rapid onset of effect.METHODOLOGY:
The US Food and Drug Administration has accepted filing of a new drug application for zuranolone, a neuroactive steroid that targets g-aminobutyric acid type A receptors (GABA A R), for the treatment of major depressive disorder (MDD) and postpartum depression.
[
add
]
[
|
|
...
]